GUIFFRE CHRISTOPHERD T. - 16 Feb 2022 Form 4 Insider Report for Pear Therapeutics, Inc.

Role
CFO, COO, Treas., & Asst. Sec.
Signature
/s/ Stacie S. Aarestad, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
16 Feb 2022
Net transactions value
$0
Form type
4
Filing time
18 Feb 2022, 15:41:25 UTC
Previous filing
07 Dec 2021
Next filing
18 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PEARQ Stock Option (Right to Buy) Award $0 +118,170 $0.000000 118,170 16 Feb 2022 Common Stock 118,170 $4.06 Direct F1
transaction PEARQ Restricted Stock Units Award $0 +150,000 $0.000000 150,000 16 Feb 2022 Common Stock 150,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying the option shall vest on January 14, 2023 and an additional 2.0833 and 1/3% of the shares shall vest on the last day of each calendar month thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of PEAR common stock.
F3 The restricted stock units shall vest and settle as to 33% of the shares on January 14, 2023, 33% of the shares on January 14, 2024 and the final 34% on January 14, 2025.